Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT · Real-Time Price · USD
0.2015
-0.0358 (-15.09%)
Oct 30, 2026, 3:31 PM EDT - Market open
Lakewood-Amedex Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Nu-3 is a locally delivered gel candidate for infected diabetic foot ulcers, supported by rapid-kill and animal-model data. The Phase IIa study is ongoing, with topline results targeted for Q1 next year; positive results could lead to Phase IIb.
-
A novel class of antimicrobials, Bisphosphocins, is advancing in clinical development for diabetic foot ulcer infections, showing rapid bacterial kill, low resistance risk, and strong preclinical and early clinical results. A phase IIA trial is set for 2024, with broader pipeline and IP strength supporting future growth.